Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1348

Shown on this page

Current sort

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Yale

Live official records

Open in full search

Conditions: Open Surgery, Lymphedema, Free Tissue Transfer, Microsurgery, Anastomosis, Surgical
Interventions: Symani Surgical System; Device
Lead sponsor: MMI (Medical Microinstruments, Inc.); Industry
Eligibility: 22 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Beverly Hills, California • New Haven, Connecticut • Tampa, Florida + 3 more

Conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Interventions: [177Lu]Lu-DOTA-TATE, Octreotide LAR; Radiation · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 20
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions: Bemarituzumab, Nivolumab, Chemotherapy, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Cerritos, California • Downey, California + 31 more

Conditions: Bronchiolitis Acute
Interventions: Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Months to 24 Months
Enrollment: 2,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 60
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more

Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 51
States / cities: Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Radium Ra 223 Dichloride; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more

Conditions: Migraine
Interventions: Eptinezumab; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Marcos, California + 17 more

Conditions: Facial Vascularized Composite Allotransplantation, Functional Recovery
Interventions: Facial Vascularized Composite Allotransplantation (VCA); Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2037
U.S. locations: 9
States / cities: Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Rejoyn, Cognitive Behavioral Therapy (CBT) exercises; Device · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Greenwich, Connecticut • New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 188
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 156 more

Conditions: Healthy
Interventions: PF-08049820, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Clinical trials in New Haven, Connecticut

Filter and sort this location

Institutions in New Haven

Live official records

A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

I-DECIDE After Bronchiolitis Hospitalization

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Facial Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults